Project Grant R01HL171283
Award Date
8/15/24
Completion Date
5/31/28
Dollars Obligated
$1.3M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,504,820.00 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University in Indianapolis to conduct research on the chronic lung disease and immune responses observed in patients following acute COVID-19 infection. The key objectives of the project are to: 1) obtain bronchoalveolar lavage (BAL) samples and peripheral blood from patients with persistent lung disease after COVID-19 for...
This $131,988 Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, supports research targeting determinants of SARS-CoV-2 host interaction in airways. Funded through the Cardiovascular Diseases Research program, the grant aims to identify master regulator proteins that mechanistically regulate SARS-CoV-2 interactions in the airways. Using organotypic airway epithelial culture and systems biology tools at Columbia University, the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), which is part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $503,637 to The University of Kentucky Research Foundation to study the mechanisms of thrombosis (blood clotting) in patients with COVID-19 infection. The research aims to investigate two novel regulatory mechanisms that lead to hemostatic and fibrinolytic dysfunction, resulting in the formation of microclots that can cause...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $480,990 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Illinois to conduct research on the role of aerocytes, a recently identified lung cell population, in promoting alveolar epithelial regeneration following acute respiratory distress syndrome (ARDS). The project aims to establish the central role of aerocytes in regulating alveolar regeneration through signaling molecules like...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $408,606 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oklahoma State University (OSU) to conduct research on the role of ERK1/2 signaling in SARS-CoV-2-induced dysregulated immunity and lung pathology. The primary objective of the 5-year study, which runs from September 2024 to June 2029, is to demonstrate the critical role of myeloid cell toll-like receptor (TLR)-ERK1/2 signaling in...
This federal Project Grant award, valued at $2,466,322.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the mechanisms by which the histone methyltransferase MLL1 regulates gene expression related to endothelial inflammation and thrombosis in severe SARS-CoV-2 infection. The key objectives are to: 1) determine how MLL1 targets promotor regions of genes involved in endothelial cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $391,250.00 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports a 3-year research project to investigate the role of the fibrinogen protein as a mediator of COVID-19-associated coagulopathy (abnormal blood clotting). Specifically, the research aims to: 1) Define the impact of therapeutic plasma exchange (TPE) on blood rheology and vascular integrity in COVID-19...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $690,626 to the Regents of the University of Michigan to study the role of type I interferon signaling in modulating acute lung injury. The research aims to: 1) identify the molecular effectors linking interferon signaling to cell cycle arrest in respiratory epithelial cells, 2) determine if inhibition of alveolar regeneration is...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to support research on immune crosstalk in lung injury and fibrosis. The key objectives are: 1) studying epithelial HB-EGF regulation of fibrosis and its interaction with myeloid cells, 2) uncovering mechanisms for impaired innate immunity against gram-positive infections...
This Project Grant award of $190,113 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the role of macrophages in facilitating lung epithelial repair following viral infections. The research will be conducted by the President and Fellows of Harvard College, leveraging their expertise in macrophage biology and lung repair mechanisms. The study seeks to 1) define when and where macrophages are required...